Ascendis Pharma (ASND) Stock
Key stats
- Market cap
- $16.58B
- Price / Earnings ratio
- 17.3x
- EPS (TTM)
- $15.87
- Volume
- Loading
- 52-week high
- $282.15
- 52-week low
- $188.08
- EPS vs analyst estimate
- -185.1%Q3 FY25 · -$1.17 vs -$0.41
Source: third-party data provider, as of November 22, 2026
EPS estimate: analyst consensus
Compare with ASND
Recent news

Ascendis Pharma A/S Q3 Earnings Call Highlights
Ascendis Pharma A/S Q3 Earnings Call Highlights
ASND

ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug
ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug
ASND

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
ASND

ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
ASND
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 48.56
- MACD 12/26/9
- 6.05
- EMA 9 of MACD
- 6.83
- MACD histogram
- -0.78
- SMA 50
- $242.58
- Price above SMA 50
- EMA 50
- $249.90
- Price above EMA 50
- SMA 200
- $240.90
- Price above SMA 200
- EMA 200
- $237.72
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 20, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 17 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
Source: third-party data provider
Latest news

Ascendis Pharma A/S Q3 Earnings Call Highlights
Ascendis Pharma A/S Q3 Earnings Call Highlights
ASND

ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug
ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug
ASND

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
ASND

ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged
ASND

Ascendis Pharma A/S Q2 Earnings Call Highlights
Ascendis Pharma A/S Q2 Earnings Call Highlights
ASND

Why Crinetics Stock Soared 99% This Week
Why Crinetics Stock Soared 99% This Week
ASND

Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
ASND

Ascendis wins U.S. approval for therapy for children with dwarfism
Ascendis wins U.S. approval for therapy for children with dwarfism
ASND

Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?
Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?
ASND

Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ
Final Trades: Ascendis Pharma, Monolithic Power, the IYC and the GPIQ
ASND
News tone: automated (AI) classification of the article's content, not a price prediction.
About Ascendis Pharma
Ascendis Pharma is applying our innovative TransCon™ technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we utilize our technology platform to create new and potentially best-in-class therapies. We currently have a pipeline of three independent, endocrinology rare disease product candidates in clinical development, and multiple preclinical programs in oncology, our second therapeutic area.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Jan Moller Mikkelsen | President, CEO, Member of Executive Board & Executive Director | 1960 |
| Mr. Scott T. Smith | CFO, Executive VP & Member of Executive Board | 1974 |
| Ms. Pedersen Anni Lotte Kirstine Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board | 1961 |
| Mr. Michael Wolff Jensen L.L.M. | Executive VP, Chief Legal Officer & Member of the Executive Board | 1971 |
| Mr. Mads Bodenhoff | Senior VP, Head of Finance & Principal Accounting Officer | 1970 |
| Mr. Chad Fugure | Vice President of Investor Relations | — |
| Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality | 1961 |
| Dr. Kennett Sprogoe Ph.D. | Executive VP and Head of Research & Product Development | 1979 |
| Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology | 1969 |
| Mr. Jay Donovan Wu | Executive VP & President of Ascendis US | 1985 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 22, 2026
Technical indicators
- RSI 14
- 48.56
- MACD 12/26/9
- 6.05
- EMA 9 of MACD
- 6.83
- MACD histogram
- -0.78
- SMA 50
- $242.58
- Price above SMA 50
- EMA 50
- $249.90
- Price above EMA 50
- SMA 200
- $240.90
- Price above SMA 200
- EMA 200
- $237.72
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 20, 2026. Technical data, not a recommendation.
Analyst views
17 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $273.00
- Average
- $317.47
- High
- $356.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -7.5 | -5.0 | ||||||||||
| 2022 | -10.4 | -7.3 | +7.8 | -21.3 | -7.2 | +9.6 | -7.6 | +6.6 | +15.9 | +15.7 | +5.4 | +0.3 |
| 2023 | +2.8 | -10.0 | -5.3 | -3.9 | +0.3 | +1.5 | +2.3 | +7.0 | -4.7 | -2.0 | +10.6 | +21.0 |
| 2024 | +1.9 | +4.3 | -0.9 | -8.9 | -4.2 | +0.8 | -0.4 | +1.4 | +10.9 | -16.2 | +8.6 | +3.1 |
| 2025 | -5.3 | +25.2 | +2.6 | +12.6 | -2.8 | -1.8 | +0.9 | +11.3 | -0.2 | -1.2 | +5.6 | +1.1 |
| 2026 | +6.0 | +4.4 | -5.5 | +0.5 | +1.4 | +21.9 | -8.9 | +8.0 | -12.5 | +10.5 | +1.5 |



